Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02220634 · ClinicalTrials.gov registry record · NA
Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension
A NA study, sponsored by National Jewish Health.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02220634 is a NA study that was terminated before completion, run by National Jewish Health. The registered enrollment target is 10 participants.
The verdict
NCT02220634, a NA study, was terminated before completion, sponsored by National Jewish Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to see if Regadenoson may offer improved ease of use, single dose administration, and better tolerance for testing for pulmonary hypertension than iNO. You will be screened to make sure Regadenoson is safe for you with a clinical evaluation, blood tests, and an ECG.
Interventions
- DRUG Regadenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-05-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02220634
The ClinicalTrials.gov registry entry for NCT02220634 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Regadenoson is the first listed.
NCT02220634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02220634 about?
NCT02220634 is a clinical study titled "Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension". The purpose of this study is to see if Regadenoson may offer improved ease of use, single dose administration, and better tolerance for testing for pulmonary hypertension than iNO. You will be screened to make sure Regadenoson is safe for you with a clinical evaluation, blood tests, and an ECG.
What is the current status of trial NCT02220634?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2014-08. Estimated completion is 2017-05-25.
What interventions are being tested in trial NCT02220634?
The interventions under investigation include: Regadenoson (DRUG).
Who is sponsoring clinical trial NCT02220634?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.